Medical News

RSS

Some small businesses see burden in 'Cadillac' tax

Kaiser Health News staff writer Jenny Gold, in collaboration with NPR, writes about this proposed tax. It could make it more difficult for small businesses to purchase health coverage.

5 Mar 2010

GSK's Japanese subsidiary begins voluntary recall of Poligrip products containing zinc

Today, the Japanese subsidiary of pharmaceutical giant, GlaxoSmithKline (GSK), announced that it would begin a voluntary recall of Poligrip products that contain zinc in that country Friday. The company's decision followed just three reports of adverse health effects in consumers of the product, sold in Japan as Poligrip EX.

5 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

Sebelius takes on health insurers

The Wall Street Journal/Dow Jones: When health insurance executives meet with Health and Human Services Secretary Kathleen Sebelius at the White House Thursday to discuss premiums, they will "face a regulator who is well-versed in the complexities of the industry." Sebelius, whose resume includes a stretch as a state insurance commissioner, "is taking aim at rising premium rates as she joins President Barack Obama's push for an overhaul of the nation's health-coverage laws.

5 Mar 2010

MED3OOO, Acryness announce strategic partnership to provide QuikBill patient billing solutions

MED3OOO, a leading healthcare management and technology company, and Acryness, a document processing and mailing organization, announce a strategic partnership to provide patient-friendly and intelligent content-driven statement solutions. The partnership will provide the MED3OOO QuikBill patient billing solutions, powered by Acryness, to MED3OOO's Revenue Cycle Management and ASP Practice Management clients.

5 Mar 2010

Toxicologists, environmental health scientists to discuss on safeguarding public health at SOT meeting

The government's leading toxicologists and environmental health scientists will share their latest scientific accomplishments, offer continuing education courses, discuss funding and training opportunities, receive input on future research priorities, and more, at the Society of Toxicology annual meeting.

5 Mar 2010

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.

5 Mar 2010

Isotechnika Pharma receives grant of $237,069 to support NICAM program

Isotechnika Pharma Inc. today announced that it has received funding approval from the National Research Council's Industrial Research Assistance Program (IRAP) for its Non-Immunosuppressive Cyclosporin Analog Molecules (NICAM) program.

5 Mar 2010

Study shows link between Vitamin D levels and basal cell carcinoma

A Henry Ford Hospital study has shown a link between Vitamin D levels and basal cell carcinoma, a finding that could lead researchers to better understand the development of the most common form of skin cancer.

5 Mar 2010

Abortion language in health care bills continues to rankle both sides

"Pro-life advocates say the Democrats' health care bill would send millions of dollars to community health care centers without restrictions to keep the money from being used to fund abortions, potentially expanding access to the procedure." The National Right to Life Group "calls the Senate bill, which could come up for a vote in the House, 'the most pro-abortion piece of legislation to come before the House of Representatives.'"

5 Mar 2010

Study: Genetic variant of LTA4H offers protection against TB and leprosy

A study into why some people are more resistant than others to diseases such as tuberculosis (TB) and leprosy has identified a new genetic variant which affects susceptibility to these diseases. The findings, published today in the journal Cell, may have implications for future treatments for the two conditions.

5 Mar 2010

Dermatologist addresses common parasitic infestations and latest treatment options at Academy Annual Meeting

If simply the thought of bedbugs, scabies and head lice makes you feel a little itchy, imagine how those affected by these common infestations feel when they learn what has been creeping around them and causing symptoms such as intense itching, red bite marks or irritated scalps.

5 Mar 2010

Obama pushes reconciliation, action on health care overhaul

In his White House speech Wednesday afternoon, President Barack Obama outlined his updated health overhaul plan and endorsed a legislative maneuver meant to move the congressional efforts on health care reform forward.

4 Mar 2010

U.S. Vascular Access Holdings acquires National Vascular Care

Fresenius Medical Care, the world’s largest provider of dialysis services and products, today announced that its subsidiary, U.S. Vascular Access Holdings, LLC has completed the acquisition of National Vascular Care Inc.

4 Mar 2010

FDA approves CSL Behring's Hizentra for PI

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.

4 Mar 2010

Heartburn drug Kapidex to be marketed under new name Dexilant

The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications – Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant.

4 Mar 2010

Scientists discover genetic cause of Quebec Platelet Disorder

For some Canadians, any cut such as from dental work or surgery can cause days or more of bleeding. Although they are not hemophiliacs, for some an ordinary bruise can balloon into the size of an orange.

4 Mar 2010

Political heat tests the President's calm composure

The Washington Post: For a president "who so famously rejects drama," recent times have marked "one of the wildest policitcal stretches in recent memory." President Obama has said during yesterday's White House speech that, at stake in this legislative struggle is the nation's ability not only to solve health care problems, but "our ability to solve any problem."

4 Mar 2010

Vaxart raises $12.5M to advance Phase I clinical trials on Avian flu vaccine

Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has closed a $12.5 million Series B financing, led by Care Capital of Princeton NJ. The funding will be used to advance the Company's lead product, an oral vaccine for Avian influenza, through Phase I clinical trials.

4 Mar 2010